Mohit Tyagi
Research Interests
Mohit Tyagi has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Jan Kihlberg
Department of Chemistry-BMC, Uppsala University, Uppsala, Sweden
2 shared publications - Peter Sjö
Drugs for Neglected Diseases initiative
2 shared publications - Vasanthanathan Poongavanam
Drug Discovery and Development Platform, Science for Life Laboratory, Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden
2 shared publications - Ahmad Y. Sheikh
Synthetic Molecules CMC R&D, AbbVie Inc., 1 N Waukegan Road, North Chicago, Illinois 60064, United States
1 shared publication Alessandro Oliva
Department of Chemistry for Life Sciences
1 shared publication- An Matheeussen
University of Antwerp Universiteitsplein 1
1 shared publication
Latest Publications
- Open Access
- 22 June 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (13) , 15702-15730
What Is in a Structure? Cell Permeability and Solubility of Series of Macrocycles and Linear Matched Pairs
Macrocycles are a highly interesting modality to modulate difficult-to-drug targets, but often reside in chemical space where obtaining sufficient cell permeability and solubility is challenging. We have determined permeability across Caco-2 cells, aqueous solubility and log D for four series of semipeptidic macrocycles and one series of linear matched molecular pairs. By using X-ray crystallography, NMR spectroscopy, and computational chemistry, unexpected permeability differences between series and matched pairs were explained by differences in conformational preferences that determine the formation of intramolecular interactions. Macrocycles that formed intramolecular NH-π interactions and hydrogen bonds were more permeable than matched pairs unable to form such interactions. The elevated permeability of linear compounds was concluded to result from their greater conformational flexibility, allowing them to shield amide bonds and expose nonpolar groups to a greater extent than their macrocyclic matched pairs. Solubility was less dependent on specific intramolecular interactions and was predominantly low at log D >2.5.
- 22 June 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (13) , 15702-15730
Open AccessWhat Is in a Structure? Cell Permeability and Solubility of Series of Macrocycles and Linear Matched Pairs
Macrocycles are a highly interesting modality to modulate difficult-to-drug targets, but often reside in chemical space where obtaining sufficient cell permeability and solubility is challenging. We have determined permeability across Caco-2 cells, aqueous solubility and log D for four series of semipeptidic macrocycles and one series of linear matched molecular pairs. By using X-ray crystallography, NMR spectroscopy, and computational chemistry, unexpected permeability differences between series and matched pairs were explained by differences in conformational preferences that determine the formation of intramolecular interactions. Macrocycles that formed intramolecular NH-π interactions and hydrogen bonds were more permeable than matched pairs unable to form such interactions. The elevated permeability of linear compounds was concluded to result from their greater conformational flexibility, allowing them to shield amide bonds and expose nonpolar groups to a greater extent than their macrocyclic matched pairs. Solubility was less dependent on specific intramolecular interactions and was predominantly low at log D >2.5.
- Open Access
- 8 October 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (20) , 18170-18193
Discovery of a Series of Macrocycles as Potent Inhibitors of Leishmania Infantum
Macrocycles are prominent among drugs for treatment of infectious disease, with many originating from natural products. Herein we report on the discovery of a series of macrocycles structurally related to the natural product hymenocardine. Members of this series were found to inhibit the growth of Plasmodium falciparum, the parasite responsible for most malaria cases, and of four kinetoplastid parasites. Notably, macrocycles more potent than miltefosine, the only oral drug used for the treatment of the neglected tropical disease visceral leishmaniasis, were identified in a phenotypic screen of Leishmania infantum. In vitro profiling highlighted that potent inhibitors had satisfactory cell permeability with a low efflux ratio, indicating their potential for oral administration, but low solubility and metabolic stability. Analysis of predicted crystal structures suggests that optimization should focus on the reduction of pi-pi crystal packing interactions to reduce the strong crystalline interactions and improve the solubility of the most potent lead.
- 8 October 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (20) , 18170-18193
Open AccessDiscovery of a Series of Macrocycles as Potent Inhibitors of Leishmania Infantum
Macrocycles are prominent among drugs for treatment of infectious disease, with many originating from natural products. Herein we report on the discovery of a series of macrocycles structurally related to the natural product hymenocardine. Members of this series were found to inhibit the growth of Plasmodium falciparum, the parasite responsible for most malaria cases, and of four kinetoplastid parasites. Notably, macrocycles more potent than miltefosine, the only oral drug used for the treatment of the neglected tropical disease visceral leishmaniasis, were identified in a phenotypic screen of Leishmania infantum. In vitro profiling highlighted that potent inhibitors had satisfactory cell permeability with a low efflux ratio, indicating their potential for oral administration, but low solubility and metabolic stability. Analysis of predicted crystal structures suggests that optimization should focus on the reduction of pi-pi crystal packing interactions to reduce the strong crystalline interactions and improve the solubility of the most potent lead.